31. Zaphirio European Journal of Heart Failure 7 (2005) 537– 541 N=306 ESC HF criteria
32. Nielsen et al. The European Journal of Heart Failure 6 (2004) 63–70 NT-pro BNP <17 pg/ml Age >=50 NT-pro BNP <11 pg/ml Age >=50 N= 345, ESC HF Dx Sens 95% Spect 68% PPV 54% NPV 97%
33.
34.
35.
36.
37. ( Circulation . 2003;107:1278-1283.) N=4300 HF patients Valheft Study
38.
39.
40. Screening for Cardiac Dysfunction CV Risk Factors As ymptomatic LV dysfx Overt Heart Failure Advanced/Terminal Heart Failure AHA/ACC Stage A B C D ?
71. RA pressure Note in intubated patients, IVC size is not reliable for RA pressure assessment (unless it is small). IVC ∆ with resp RA pressure <1.5 cm collapse 0-5 mmhg nl (1.5-2.5) >50% 5-10 nl <50% 11-15 >2.5 <50% 16-20 >2.5 no change >20
81. N Engl J Med 2005;352:225-37 N=2521 LVEF 35% NYHA class II
82.
83.
84.
85.
86.
87.
88.
Editor's Notes
If we turn back to evidence-based data for just a moment. All of you are aware of this study, COMPANION trail, published in NEJM showing that patients with CRT or CRT D who met the study criteria here had a significant reduction in primary outcomes including mortality and HF hosp from any causes and secondary endpoints including any death.
About a year later, a CARE HF study published in NEJM actually showed the same thing for survival benefit of the CRT.
Not only survival benefits of CRT, functional benefits including …. Have been demonstrated in many literatures.
Not only CRT, but also ICD has survival benefit in selected patients with HF. Data from SCD heft has clearly shown that ICD therapy significantly reduce mortality compared with placebo.